Druckversion

Archiv: Mitteilungen

20.08.2014

Von Willebrand disease: The nasal spray that could stop the misery of heavy periods

The nasal spray that could stop the misery of heavy periodswww.dailymail.co.ukFor decades, Helen Campbell, 42, from Leeds, suffered from heavy periods and nosebleeds. Her periods could last for 21 days. [mehr]


20.08.2014

Achillion's Hepatitis C Drug Cures All Patients in Mid-stage Trial

Achillion's HCV Drug Cures All Patients in Mid-stage Trialwww.medscape.comAchillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no...[mehr]


19.08.2014

Call for proposal for the Novo Nordisk HERO Research Grant 2014 are open until 31 August 2014

Call for proposal for the Novo Nordisk HERO Research Grant 2014 are open until 31 August 2014 [mehr]


15.08.2014

New Methods May Make CJD Testing Easier

New Methods May Make CJD Testing Easierwww.medpagetoday.comAmplification procedures for abnormally folded prion proteins enabled accurate diagnosis of Creutzfeldt-Jakob disease from nasal and urine samples, two small pilot trials...[mehr]


14.08.2014

Rekombinanter Gerinnungsfaktor VIII aus menschlichen Zellen (Nuwiq®) in der EU zugelassen

Die Europäische Kommission hat die Zulassung für Nuwiq® (simoctocog alfa) zur Behandlung und Prophylaxe bei  Hämophilie A erteilt. Wie die Firma Octapharma mitteilt, ist Nuwiq® das erste FVIII-Konzentrat in Europa,...[mehr]


12.08.2014

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia

Alnylam Pharmaceuticals, Inc. - Alnylam Receives Orphan Drug Designations in the European Union...investors.alnylam.com--(BUSINESS WIRE)-- . (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the (COMP) has...[mehr]


12.08.2014

Baxter Opens its First State-of-the-Art Biologics Facility in Asia, Announces Expansion Plans with New Processing Suite

Baxter U.S. - Baxter Opens its First State-of-the-Art Biologics Facility in Asia, Announces...www.baxter.comBaxter Opens its First State-of-the-Art Biologics Facility in Asia, Announces Expansion Plans with New Processing...[mehr]


06.08.2014

European Commission publishes approval of Octapharma’s human cell line recombinant FVIII (Nuwiq®) across all age groups in haemophilia A

News Single View :: Octapharma AGwww.octapharma.comClick here to access a map displaying the locations of Octapharma offices and plants, if you require information on Octapharma activities in a country not listed, please contact...[mehr]


06.08.2014

USA: Oregon Medicaid Targets Expensive Hepatitis Drug

Oregon Medicaid Targets Expensive Hepatitis Drugabcnews.go.comAn Oregon Medicaid committee is expected Thursday to significantly scale back access to an effective — but expensive — new drug used to treat hepatitis C. The decision...[mehr]


Treffer 1 bis 10 von 974
<< Erste < Vorherige 1-10 11-20 21-30 31-40 41-50 51-60 61-70 Nächste > Letzte >>